Treatment of Hypoactive Sexual Desire Disorder Among Women: General Considerations and Pharmacological Options
Abstract
Hypoactive sexual desire disorder (HSDD) is a persistent or recurrent absence of sexual fantasies and desire for sexual activity, causing marked personal distress or interpersonal difficulties. HSDD affects 10% of U.S. women and is associated with depression and other negative emotional states. It is imperative that psychiatrists are competent to make this diagnosis and are aware of available treatment options. A full psychiatric and medical history are necessary to identify potential causes or contributing factors that may need to be addressed first. The authors discuss the diagnostic tools available as well as general diagnostic considerations for psychiatrists. Given its importance in the understanding of the available treatments for this disorder, the pathophysiology behind HSDD is reviewed. The authors emphasize the treatment of HSDD, including general treatment considerations, treatment in the context of depression, and psychotherapy and medications that have been approved by the U.S. Food and Drug Administration.
Hypoactive sexual desire disorder (HSDD) is defined in the DSM-IV-TR as a persistent or recurrent absence of sexual fantasies and desire for sexual activity, which causes marked personal distress or interpersonal difficulties. The symptoms are not better explained by another axis I diagnosis and are not due to the direct physiological effects of a drug or medical condition. It is further classified into lifelong or acquired, and generalized or situational (1). The International Society for the Study of Women’s Sexual Health developed a definition for HSDD that states that either a lack of motivation for sexual activity or a lack of desire to initiate or participate in sexual activity must be accompanied by clinically significant personal distress and must be present for at least 6 months (2).
The newer DSM-5 merged two of the female sexual dysfunction disorders into female sexual interest/arousal disorder, eliminating HSDD and female sexual arousal disorder. However studies on treatment options for HSDD have used DSM-IV-TR criteria. The ICD-11 available January 1, 2022, has a separate chapter entitled “Conditions Related to Sexual Health,” which integrates some mental health and behavioral disorders with some genitourinary disorders. This chapter returns the diagnoses to parallel diagnoses for men and women including HSDD and orgasmic dysfunction, except for distinct clinical presentations (female sexual arousal disorder and erectile dysfunction), and it also adds pelvic pain/penetration disorder for both men and women.
HSDD affects 10% of U.S. women (3). It is also associated with depression and other negative emotional states (4, 5). Therefore, it is imperative that psychiatrists are competent to make this diagnosis and are aware of what treatment options are available for their patients.
Among the subtypes of HSDD, the generalized acquired form is the one that could benefit from pharmacological treatment. Other subtypes, such as lifelong and situational, are not discussed in this review.
Diagnosis
To make the diagnosis, a sexual history and use of the Decreased Sexual Desire Screener are recommended (Figure 1) (6). The Decreased Sexual Desire Screener is quick and effective, and it requires no specific training to administer. It is a validated instrument for confirming the diagnosis of generalized acquired HSDD. It consists of five “yes-no” questions. If the patient answers “yes” to the first four questions and “no” to the items on question 5, they have generalized acquired HSDD. Any items checked in question 5 may represent initiating events or modifiable factors for early intervention. This instrument can also help initiate the dialogue between patient and physician; moreover, it can screen for potential etiologies of HSDD (Figure 1) and is in the public domain, so it can be used freely in clinical practice.
FIGURE 1. Decreased Sexual Desire Screenera
aFrom Clayton et al. (6). Reprinted with permission from Elsevier.
Diagnostic Considerations for Psychiatrists
It is important to obtain a full psychiatric and medical history to identify potential causes or contributing factors that may need to be addressed first. Screening for depression is particularly important, given its bidirectional relationship with HSDD. Studies have shown that the risk of sexual dysfunction is increased by 50%–70% among women with depression. Inversely, women with sexual dysfunction have a 130%–210% increased risk for depression (7, 8).
Sexual and/or physical trauma or psychological factors can cause sexual dysfunction and likely require the addition of psychotherapy to the treatment plan. Substance abuse or dependence can also cause sexual dysfunction and should be addressed separately and before interventions specific for HSDD.
Certain antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs), can cause sexual dysfunction and can be managed with a dose reduction, switch to a different antidepressant, or addition of an antidote. Some antipsychotics, particularly risperidone or first-generation antipsychotics, also cause sexual dysfunction; therefore, it might be useful to obtain a prolactin level in these cases. Treatment recommendations for depression and antidepressant-induced sexual dysfunction are discussed in the following sections.
Providers should also screen for other sexual problems such as arousal or orgasm dysfunction and sexual pain. If present, these conditions might be contributing to or causing the low sexual desire.
It is worth pointing out that numerous medical conditions can cause or contribute to low sexual desire. Hypertension, diabetes, metabolic syndrome, hypothyroidism, urinary incontinence, neurological disorders, and malignancy have all been associated with low sexual desire (9–11).
Several classes of medications have also been associated with low sexual desire (Table 1). Broadly speaking, antihypertensive medications, hormonal preparations, narcotics, psychotropics, and chemotherapeutic agents have all been associated with decreased sexual desire (12). Because of widespread use, it is important to inquire whether the patient is on an oral contraceptive pill (OCP). Checking sex hormone binding globulin (SHBG) and testosterone levels (total and free) might be helpful for this subset of patients, given that OCPs can raise levels of SHBG, which increase binding of testosterone, resulting in a decrease in free and bioavailable testosterone. Although low testosterone is not diagnostic of HSDD, treatment with testosterone may increase sexual desire.
| Medication type | Examples |
|---|---|
| Cardiac and antihypertensive | Lipid-lowering medications, beta-blockers, clonidine, digitalis, methyldopa, spironolactone |
| Hormonal | Androgen antagonists, danazol, GnRH agonists and analogs, oral contraceptives, tamoxifen |
| Opioids | Any opioids used chronically, methadone |
| Psychotropic | Antipsychotics, barbiturates, benzodiazepines, lithium, MAOIs (oral), phenytoin, SSRIs, SNRIs, TCAs |
| Other | Aromatase inhibitors, chemotherapy, histamine 2 receptor blockers, nonsteroidal anti-inflammatory agents, ketoconazole |
a
GnRH, gonadotropin-releasing hormone; MAOIs, monoamine oxidase inhibitors; SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin-norepinephrine reuptake inhibitors; TCAs, tricyclic antidepressants.
Pathophysiology of HSDD
HSDD is thought to be in part because of an imbalance between excitatory and inhibitory pathways involved in sexual response and behavior in the brain. Generally speaking, dopamine, norepinephrine, testosterone, estrogen, and progesterone are excitatory, whereas serotonin, prolactin, and opioids are inhibitory of sexual desire and response. Pharmacological treatments for HSDD target some of the neurotransmitters and hormones involved in these pathways.
Treatment
General Considerations
We recommend first assessing the patient’s motivation for treatment and their personal preferences. A variety of treatment options are available for HSDD, including lifestyle modifications and education, psychotherapy, sex therapy, and pharmacotherapy. Treatment should be patient centered. Involving the patient’s partner should be considered. It is also important to assess whether the level of distress is significant enough to consider treatment options that carry the risk of adverse effects.
It is important to screen for contributing psychological factors. Examples include relationship strain, underlying beliefs about sex, history of trauma, and body image issues. In these cases, the appropriate psychotherapy modality to treat these issues should be part of the treatment plan.
If there is concern for an underlying medical condition or medications causing the symptoms, a referral to internal medicine or the patient’s primary care provider should be made. If pain with sexual activity is present, the patient should be referred to gynecology for a targeted examination.
Treatment of HSDD in the Setting of Depression
If depression is present, it should be treated first because untreated major depressive illness is associated with sexual dysfunction. As mentioned earlier, SSRIs, SNRIs, and TCAs can cause sexual dysfunction. For all four classes of antidepressants, sexual dysfunction is numerically but not statistically significantly worse at higher doses (15). Antidepressants that do not cause sexual dysfunction, or that cause it to a lesser degree, are preferred (Table 2). These antidepressants include bupropion and mirtazapine as well as two drugs with serotonin reuptake inhibitor effects as part of their mechanism of action: vortioxetine and vilazodone (16). Vortioxetine recently had a change to its label that states it causes significantly less sexual dysfunction than SSRIs at rates similar to placebo at doses≤10 mg for women and at doses≤15 mg for men. Should sexual dysfunction occur at higher doses, decreasing the dose may improve sexual function.
| Treatment characteristic | Antidepressant-psychotropic | Antipsychotic |
|---|---|---|
| Low rates of sexual side effects | Bupropion, mirtazapine, vilazodone, vortioxetine | Aripiprazole, brexpiprazole |
| Useful for augmentation of SSRI and SNRI | Bupropion,b buspirone,b flibanserin | Aripiprazole |
a
SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor.
b
Not approved by the U.S. Food and Drug Administration.
If augmentation with an antipsychotic is needed, aripiprazole and brexpiprazole are preferred options because they have been shown to have a low rate of sexual side effects compared with other antipsychotics (17, 18). If the patient is already on one of these agents, assess whether it is contributing to the sexual dysfunction. Reducing the dose or switching to one of the antidepressants mentioned earlier can be helpful (14, 19). Adjunctive treatment with bupropion (20–22) or buspirone (23, 24) has also been shown to decrease sexual side effects. There is also evidence that adjunctive treatment with mirtazapine can decrease sexual side effects from SSRIs (25).
If insomnia is present, it is recommended that the sleep disturbance be treated independently and to monitor for improvement of sexual symptoms. A study showed that higher insomnia scores and shorter sleep duration were associated with decreased sexual function (26). Flibanserin, which is discussed later, can also potentially help with sleep because of its sedating effects.
Psychotherapy
There are three types of psychological interventions that have been found effective in treating or helping with female sexual dysfunction and symptoms of HSDD.
Behavior therapy attempts to target sexual dysfunction through a combination of communication skills training, education, and sensate focus exercises (27).
Cognitive-behavioral therapy (CBT) can be helpful by challenging unrealistic beliefs contributing to low sexual desire and by changing maladaptive behaviors that perpetuate HSDD. A review of psychological treatments for HSDD found three studies in which CBT was effective for women with HSDD compared with a waitlist control group (28).
Mindfulness-based CBT can help the patient increase awareness of the present moment, minimizing cognitive distractions during sexual activity and enhance awareness of pleasurable sensations (29, 30). Two studies found positive results with mindfulness training among women with HSDD (28). Group mindfulness-based therapy has also been shown to improve sexual desire among women (31, 32).
Resources might be limited depending on the community; therefore, it might be beneficial to cultivate relationships with providers who have expertise in these types of psychotherapy.
Pharmacological Options
Flibanserin.
Flibanserin (Addyi) was approved in 2015 by the U.S. Food and Drug Administration (FDA) for treatment of generalized acquired HSDD among premenopausal women.
Its mechanism of action is exerted through serotonin 1A (5HT1A) receptor agonism and serotonin 2A (5HT2A) receptor antagonism. This process reduces serotonin inhibition of excitatory neurotransmitters and thus indirectly increases release of dopamine and norepinephrine (33, 34).
Three randomized, double-blind, placebo-controlled trials demonstrated that flibanserin was efficacious for HSDD symptoms compared with placebo (35–37). All three studies were conducted among premenopausal women, and all were 24 weeks long. Efficacy was measured with the Female Sexual Function Index desire subscale (FSFI-D); Female Sexual Distress Scale–Revised Item 13 (FSDS-R13), which measures distress associated with sexual desire; and Satisfying Sexual Events (SSE), as determined by the woman. All efficacy endpoints in the phase 3 studies demonstrated statistical significance in change from baseline to endpoint over placebo. Relative to placebo, flibanserin had an effect size of 0.29–0.44 (desire) and 0.24–0.44 (distress). Improvement was seen after 4 weeks of daily dosing. One study found that 50 mg given at bedtime was efficacious (36); however, another study did not find this dose to separate from placebo (35). All studies found that 100-mg daily dosing was effective in approximately 50% of women. Responders found the effect to be clinically meaningful.
A 52-week open-label extension study found that flibanserin was safe and well tolerated. Sexual function improved among participants who were initially nonremitters and was maintained over time in remitters (38).
Even though flibanserin is not indicated for postmenopausal women, evidence suggests that it is also effective among this population (39). The recommended dose is 100 mg given once daily at bedtime. When assessing for improvement, one should inquire about changes in sexual desire, reduction in distress related to sexual dysfunction, and satisfaction with the treatment. If no improvement occurs after 8 weeks, one should consider discontinuing this medication.
Flibanserin is safe to use concomitantly with SSRIs and SNRIs. A small randomized, placebo-controlled trial demonstrated no serious adverse effects and no instances of suicidal ideation and behavior when combining flibanserin 100 mg daily with a stable SSRI or SNRI treatment regimen (40).
The most common adverse reactions (incidence≥2%) include dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth. Hypotension and syncope have been reported, and its package insert has a warning for these conditions (41).
Previously, concomitant use with alcohol was contraindicated and required a risk evaluation and mitigation strategy (REMS) because of concerns for orthostatic hypotension and syncope. Studies have demonstrated that it is safe to use flibanserin with alcohol. Taking this medication 2, 4, and 6 hours after ethanol consumption did not increase the incidence of hypotension, orthostatic hypotension, or syncope compared with flibanserin or ethanol alone (42–44). Thus, the REMS program was discontinued, and the label was changed to recommend not using flibanserin within 2 hours of alcohol consumption.
Flibanserin does not appear to prolong the corrected QT interval (41). It is primarily metabolized by cytochrome P450 3A4 (CYP3A4) and cytochrome P450 2C19 (CYP2C19); therefore, one should review the patient’s medication list for moderate and strong inhibitors or inducers of these enzymes. The risk of severe hypotension is increased with CYP3A4 inhibitors. Examples of strong CYP3A4 inhibitors include clarithromycin, HIV protease inhibitors, ketoconazole, and grapefruit juice. Strong inducers of CYP3A4 include phenytoin, phenobarbital, rifampin, carbamazepine, and St. John’s wort. Strong inhibitors of CYP2C19 include fluoxetine, fluvoxamine, proton-pump inhibitors, antifungals, and benzodiazepines.
Flibanserin can increase the concentration of drugs transported by P-glycoprotein (P-gp). It is recommended to increase monitoring of concentrations of drugs transported by P-gp that have a narrow therapeutic index, such as digitalis and rapamycin.
The use of flibanserin is contraindicated in hepatic impairment because there is a 4.5-fold increase to flibanserin exposure in this population. Its use in pregnancy and breastfeeding has not been studied; therefore, it is not recommended.
Currently, this medication costs $99 per month without insurance. However, discounts as low as $20 per month for patients with commercial insurance can be found at https://addyi.com/howtosave.
Bremelanotide.
Bremelanotide (Vyleesi) was approved in 2019 by the FDA for treatment of generalized acquired HSDD among premenopausal women.
Bremelanotide is a melanocortin 4 receptor (MC4R) agonist. Neurons expressing the MC4R are present throughout the central nervous system (45). The mechanism by which bremelanotide improves HSDD is unknown, but it is thought to increase excitation by enhancing dopamine and norepinephrine activity.
The FSFI-D, item 13 of the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO), and SSE were also used in the phase 3 studies and demonstrated that bremelanotide is significantly more effective than placebo (46). The combined effect size for the two phase 3 studies relative to placebo was 0.39 for FSFI-D and 0.27 for FSDS-DAO item 13. The response rate for bremelanotide was 58.2% versus 35.6% for placebo in the integrated phase 3 data set. This response was considered clinically meaningful by the study participants. An extension study also showed that after 52 weeks, response to this medication was maintained (47).
The recommended dose is 1.75 mg administered subcutaneously in the abdomen or thigh via an autoinjector, on an as-needed basis. Patients should inject the medication at least 45 minutes before a sexual encounter. It is not recommended to use more than one dose within 24 hours, or more than eight doses within 1 month.
As with flibanserin, one should inquire about changes in sexual desire, reduction in distress related to sexual dysfunction, and satisfaction with the treatment to assess for treatment response. If no improvement occurs after 8 weeks, one should consider discontinuing this medication.
The most common adverse reactions (incidence≥4%) include nausea, flushing, headache, vomiting, and adverse site reactions. Nausea is the most common adverse reaction. In placebo-controlled trials, 40% of patients receiving bremelanotide reported nausea compared with 1% of patients receiving placebo. Hyperpigmentation of the face, gingiva, and breasts has also been reported (48).
Bremelanotide can cause transient increases in blood pressure, and it is contraindicated in uncontrolled hypertension. Providers should consider the patient’s cardiovascular risk and ensure that blood pressure is well controlled.
Of note, bremelanotide can significantly decrease the absorption of oral naltrexone, and its concomitant use is not recommended. The use of intramuscular naltrexone can be an alternative for this subset of patients.
This medication also has cost savings available online at https://www.vyleesi.com/getting-started. With these discounts, the current cost varies between $0 and $99 per 4-pack of autoinjectors.
Testosterone.
Although approved in Europe for treatment of HSDD among women with surgical menopause, it is an off-label treatment option in the United States. Studies on testosterone for HSDD have been largely conducted among women who have undergone natural or surgical menopause. Evidence is lacking for premenopausal women, and should a woman become pregnant, fetal exposure may be associated with significant negative consequences.
Three randomized, double-blind, placebo-controlled trials have shown that a 300-μg/d transdermal testosterone patch was superior to placebo in improving symptoms of HSDD. Women who received this medication reported improvement in satisfying sexual events as well as a decrease in levels of distress. Lower testosterone doses were not effective (49–52). This product was not approved in the United States because of lack of information about long-term consequences. These concerns have not been borne out in use in other countries.
Transdermal use is recommended. Oral or intramuscular preparations are not recommended because of high variability of absorption, which typically achieves supraphysiologic levels and increases the risk of adverse effects.
Improvement of symptoms is expected within the first 3 months of treatment. If the patient does not experience improvement in symptoms after 3–6 months, consider discontinuing treatment (53).
The most common side effects are acne, application site reactions, breast pain, headache, and hirsutism. In several studies, liver function, lipid profile, hematologic tests, and clotting measures remained essentially unchanged (49–52).
Baseline and follow-up testosterone levels should be obtained. Levels should be maintained within normal ranges. Short-term safety data are reassuring when testosterone levels are maintained within normal levels (54). However, long-term data are limited to observational studies, including safety data with regard to breast cancer and cardiovascular events (55).
Testosterone formulations for women are not widely available. Most clinicians will have to use topical formulations for men but at a much lower dose, generally one-seventh to one-tenth of approved doses for men to avoid virilization. Compounded formulations are another option.
Conclusions
HSDD affects 10% of U.S. women. Assessment should include comorbid medical, psychiatric, and sexual disorders and their associated treatments, which may inform management. Addressing modifiable factors and utilizing targeted interventions will provide optimal care to women with HSDD.
Acknowledgments
The authors thank Stephen Furry for assistance with formatting and submitting the article.
References
1.
Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text rev. Washington, DC, American Psychiatric Publishing, 2000
2.
Clayton AH, Goldstein I, Kim NN, et al: The International Society for the Study of Women’s Sexual Health process of care for management of hypoactive sexual desire disorder in women. Mayo Clin Proc 2018; 93:467–487
3.
Shifren JL, Monz BU, Russo PA, et al: Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008; 112:970–978
4.
Kingsberg SA: Attitudinal survey of women living with low sexual desire. J Womens Health 2014; 23:817–823
5.
Dennerstein L, Koochaki P, Barton I, et al: Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med 2006; 3:212–222
6.
Clayton AH, Goldfischer ER, Goldstein I, et al: Validation of the Decreased Sexual Desire Screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med 2009; 6:730–738
7.
Zeleke BM, Bell RJ, Billah B, et al: Hypoactive sexual desire dysfunction in community-dwelling older women. Menopause 2017; 24:391–399
8.
Atlantis E, Sullivan T: Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. J Sex Med 2012; 9:1497–1507
9.
Bitzer J, Giraldi A, Pfaus J: Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP part 1). J Sex Med 2013; 10:36–49
10.
Kingsberg SA, Rezaee RL: Hypoactive sexual desire in women. Menopause 2013; 20:1284–1300
11.
Alvisi S, Baldassarre M, Lambertini M, et al: Sexuality and psychopathological aspects in premenopausal women with metabolic syndrome. J Sex Med 2014; 11:2020–2028
12.
Buster JE: Managing female sexual dysfunction. Fertil Steril 2013; 100:905–915
13.
Stahl SM: Circuits of sexual desire in hypoactive sexual desire disorder. J Clin Psychiatry 2010; 71:518–519
14.
Clayton AH: The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet 2010; 110:7–11
15.
Clayton AH, Pradko JF, Croft HA, et al: Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63:357–366
16.
Jing E, Straw-Wilson K: Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review. Ment Health Clin 2016; 6:191–196
17.
Clayton AH, Baker RA, Sheehan JJ, et al: Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. BMC Res Notes 2014; 7:459
18.
Markovic M, Gallipani A, Patel KH, et al: Brexpiprazole. Ann Pharmacother 2017; 51:315–322
19.
Hirschfeld RM: Management of sexual side effects of antidepressant therapy. J Clin Psychiatry 1999; 60(Suppl 14):27–35
20.
Clayton AH, Warnock JK, Kornstein SG, et al: A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004; 65:62–67
21.
Taylor MJ, Rudkin L, Bullemor-Day P, et al: Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2013; 5:CD003382
22.
Kingsberg SA, Clayton AH, Pfaus JG: The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder. CNS Drugs 2015; 29:915–933
23.
Landén M, Eriksson E, Agren H, et al: Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999; 19:268–271
24.
Clayton AH, El Haddad S, Iluonakhamhe JP, et al: Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf 2014; 13:1361–1374
25.
Ozmenler NK, Karlidere T, Bozkurt A, et al: Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol 2008; 23:321–326
26.
Kling JM, Manson JE, Naughton MJ, et al: Association of sleep disturbance and sexual function in postmenopausal women. Menopause 2017; 24:604–612
27.
Sarwer DB, Durlak JA: A field trial of the effectiveness of behavioral treatment for sexual dysfunctions. J Sex Marital Ther 1997; 23:87–97
28.
Pyke RE, Clayton AH: Psychological treatment trials for hypoactive sexual desire disorder: a sexual medicine critique and perspective. J Sex Med 2015; 12:2451–2458
29.
Silverstein RG, Brown AC, Roth HD, et al: Effects of mindfulness training on body awareness to sexual stimuli: implications for female sexual dysfunction. Psychosom Med 2011; 73:817–825
30.
Arora N, Brotto LA: How does paying attention improve sexual functioning in women? A review of mechanisms. Sex Med Rev 2017; 5:266–274
31.
Brotto LA, Basson R, Luria M: A mindfulness-based group psychoeducational intervention targeting sexual arousal disorder in women. J Sex Med 2008; 5:1646–1659
32.
Brotto LA, Basson R: Group mindfulness-based therapy significantly improves sexual desire in women. Behav Res Ther 2014; 57:43–54
33.
Stahl SM: Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr 2015; 20:1–6
34.
Stahl SM, Sommer B, Allers KA: Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med 2011; 8:15–27
35.
Katz M, DeRogatis LR, Ackerman R, et al: Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 2013; 10:1807–1815
36.
Thorp J, Simon J, Dattani D, et al: Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 2012; 9:793–804
37.
Derogatis LR, Komer L, Katz M, et al: Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med 2012; 9:1074–1085
38.
Jayne C, Simon JA, Taylor LV, et al: Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med 2012; 9:3180–3188
39.
Simon JA, Kingsberg SA, Shumel B, et al: Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause 2014; 21:633–640
40.
Clayton AH, Croft HA, Yuan J, et al: Safety of flibanserin in women treated with antidepressants: a randomized, placebo-controlled study. J Sex Med 2018; 15:43–51
41.
Addyi (Flibanserin) [package insert]. Bridgewater, NJ, Sprout Pharmaceuticals, 2016
42.
Simon JA, Clayton AH, Parish SJ, et al: Effects of alcohol administered with flibanserin in healthy premenopausal women: a randomized, double-blind, single-dose crossover study. J Sex Med 2020; 17:83–93
43.
Millheiser L, Clayton AH, Parish SJ, et al: Safety and tolerability of evening ethanol consumption and bedtime administration of flibanserin in healthy premenopausal female subjects. Sex Med 2019; 7:418–424
44.
Simon JA, Clayton AH, Kingsberg SA, et al: Effects of timing of flibanserin administration relative to alcohol intake in healthy premenopausal women: a randomized, double-blind, crossover study. J Sex Med 2019; 16:1779–1786
45.
Mayer D, Lynch SE: Bremelanotide: new drug approved for treating hypoactive sexual desire disorder. Ann Pharmacother 2020; 54:684–690
46.
Kingsberg SA, Clayton AH, Portman D, et al: Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019; 134:899–908
47.
Simon JA, Kingsberg SA, Portman D, et al: Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019; 134:909–917
48.
Vyleesi (Bremelanotide) [package insert]. Waltham, MA, AMAG Pharmaceuticals, 2019
49.
Simon J, Braunstein G, Nachtigall L, et al: Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90:5226–5233
50.
Buster JE, Kingsberg SA, Aguirre O, et al: Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105:944–952
51.
Shifren JL, Davis SR, Moreau M, et al: Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006; 13:770–779
52.
Braunstein GD, Sundwall DA, Katz M, et al: Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005; 165:1582–1589
53.
Wierman ME, Arlt W, Basson R, et al: Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:3489–3510
54.
Davis SR, Braunstein GD: Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2012; 9:1134–1148
55.
Nachtigall L, Casson P, Lucas J, et al: Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol 2011; 27:39–48
Information & Authors
Information
Published In
History
Published in print: Winter 2021
Published online: 28 January 2021
Keywords
Authors
Funding Information
Dr. Clayton has received grants from Janssen, Relmada Therapeutics, and Sage Therapeutics. Dr. Clayton has also received advisory board or consultant fees from Acadia, Alkermes, Allergan, Fabre-Kramer, Ovoca Bio, PureTech Health, S1 Biopharma, Sage Therapeutics, Takeda/Lundbeck, and WCG MedAvante-ProPhase. In addition, Dr. Clayton has received royalties from Ballantine Books/Random House and Guilford Press and holds the copyright of the Changes in Sexual Functioning Questionnaire. Finally, Dr. Clayton owns shares or restricted stock units in Euthymics, Mediflix, and S1 Biopharma. Dr. Pachano Pesantez reports no financial relationships with commercial interests.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).